Authors
Latest:
Beyond the Science: Commercial Implications From ASCO 2017Four strategic takeaways from this year's that are important for pharma oncology leaders.
Latest:
Biotech Investor Sentiment Climbing Steadily, with Growing Enthusiasm Heading into 2025The sector's XBI is up 15% year-to-date; rate cuts, election outcome, and M&A are viewed as tailwinds.
Latest:
The Myriad Ruling: Six Points Every Biotech CEO Must ConsiderLast week, the US Supreme Court issued a long-awaited decision in Myriad Genetics, which sent shockwaves through the very foundation of the biotech industry
Latest:
Accept It, Wikipedia Is a Public Health Issue. Now Let's Fix It.Medical articles on Wikipedia receive about 150 million page views per month, and nearly 50% of practicing physicians use Wikipedia as an information source for providing medical care. And while Wikipedia itself has disclaimers that information included on its site may be inaccurate,
Latest:
Marketing is Pre-SalesNot long ago, I was privy to a discussion taking place in a large drug development services company.
Latest:
Five Ways Advanced Social Intelligence Guides Pharma StrategyWithin the billions of daily comments from individuals across open social sources lies deep intelligence into markets, brands, patients, caregivers, healthcare providers and competitors.
Latest:
Drug Patents Under Fire in BrazilOne of the most promising pharmaceutical markets of the future is Brazil, a nation of nearly 200 million people with a universal healthcare system.
Latest:
Drug Patents Under Fire in BrazilOne of the most promising pharmaceutical markets of the future is Brazil, a nation of nearly 200 million people with a universal healthcare system.
Latest:
Protecting Your Online ReputationFor CEOs who have spent long years and countless funds building a solid pharmaceutical brand and life-changing drugs, discovering defamatory remarks about your company online can come as quite a shock.
Latest:
Dissecting ACA's Section 6004: Tipping the Balance on Sampling Controls?With the Affordable Care Act [ACA] officially settling into the US’ political landscape, a pressing – but little noticed – issue is the provisions for increased compliance on industry promotion practices.
Latest:
Three Questions to Ask About Your Life Sciences PatentsThe decisions you make today about patents – what, when and where to file – could have implications tantamount to billions of dollars in R&D investment and sales over the next two decades.
Latest:
The Pharma Marketers Guide to Medication AdherenceImproving brand adherence rates requires pharma marketers to have access to two growing bodies of knowledge. These are: 1) carefully evaluated evidence for what can improve brand revenue, and 2) informed forecasts of trends.
Latest:
Drug Innovation: Alive and Well at ASCO!This year’s annual meeting of the American Society of Clinical Oncology (ASCO), which ended on Tuesday, provided many examples of emerging therapies that offer new hope to even those patients with metastatic disease.
Latest:
The Digital World is Changing Fast. Can You Keep Up?I’ve been doing this digital thing for some time now. I’ve been part of and witnessed many changes in our digital world.
Latest:
U.S. Biosimilars Under Threat?While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the U.S. may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for biosimilars.
Latest:
My Healthcare's Better Than Your HealthcareLong before the current debate on health care started, there was a different war brewing. For decades, people have been fighting over which program and plan is best: healthcare provided to government workers, military personnel or civilians?
Latest:
Patent Filing to Drug Approval: A Difficult Journey Even for the MightyThe UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years.
Latest:
Co-Pay Offset Programs and the New Health Insurance Marketplace: Will the Feds Say No?As the health insurance marketplaces begin enrollment this week and go live on January 1, 2014, several issues continue to be a source of significant confusion to manufacturers, payers and the millions of consumers purchasing health insurance for the first time through an exchange.
Latest:
Pricing Management: It's All About the DataAny pricing or revenue management initiative is only as good as the information on which it is based.
Latest:
Talkback from Tufts: Defending R&D CostsWilliam Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points.
Latest:
Why Don't Those Damn Marketers 'Do' Digital?Over the last few years I’ve worked with pharma marketers trying to preach and teach the virtues of digital channels. It has been a thankless task, with bucket loads of blood, sweat, and tears of frustration.
Latest:
World Health Assembly Underlines Pharma's Global ChallengesSusan Crowley reviews the hotly debated agenda items from last month's World Health Assembly (WHA) in Geneva, Switzerland.
Latest:
Trump: 'Major Tariff' on Pharmaceuticals Coming Soon“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.
Latest:
ESG: Applying Lessons From Consumer MarketA prime opportunity for pharma to raise its strategic game in ESG.
Latest:
Supply Chain Analytics: Pharma’s Next Big BetExamining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.
Latest:
Supply Chain Analytics: Pharma’s Next Big BetExamining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.
Latest:
Beyond the Blame Game: How Pharma is Learning to CollaborateIn a follow-up to our November CEO profile, Novo Nordisk’s Jesper Høiland writes how pharma companies and insurers are learning to collaborate.
Latest:
Marketing: Beware the Hidden Forces of Behavioral EconomicsBrand success can hinge on discovering the deeper motivations of customers and addressing the cognitive biases that result.
Latest:
FDA’s Breakthrough Therapy DesignationThree key questions dominate the agency’s Breakthrough Therapy Designation program since its 2012 launch.
